Pharmacologic management of heart failure caused by systolic dysfunction

American Family Physician

Volumn 77, Issue 7, 2008, Pages

  Chavey, William E ^a,b   Bleske, Barry E ^a   Van Harrison, R ^a   Hogikyan, Robert V ^a   Kesterson, Sean K ^a   Nicklas, John M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; BUCINDOLOL; BUMETANIDE; CANDESARTAN HEXETIL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ISOSORBIDE 2 NITRATE; ISOSORBIDE DINITRATE; LISINOPRIL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; HYDRAZINE; HYDRAZINE DERIVATIVE;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE OVERLOAD; HUMAN; HYPERKALEMIA; INCIDENCE; MASTALGIA; MORTALITY; OUTPATIENT; PRIMARY MEDICAL CARE; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SYSTOLIC DYSFUNCTION; UNITED STATES; HOSPITALIZATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIGOXIN; DIURETICS; HEART FAILURE; HUMANS; HYDRAZINES; ISOSORBIDE DINITRATE; SEVERITY OF ILLNESS INDEX; SYSTOLE; VASODILATOR AGENTS;

EID: 44449103648     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. American Heart Association. Heart disease and stroke statistics - 2007 update. Dallas, Tex.: American Heart Association; 2007. http://www. americanheart.org/downloadable/heart/1166712318459HS-StatsInsideText.pdf. Accessed october 17, 2007.
2. Burt CW, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999-2000. Vital Health Stat 13. 2004;(157):1-70.
3. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38(7):2101-2113.
4. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575-1581.
5. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-1355.
6. Packer M, Coats AJ, Fowler MB, et al.; for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-1658.
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007. (Pubitemid 29271744)
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. (Pubitemid 29037695)
9. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659-1667.
10. Poole-Wilson PA, Swedberg K, Cleland JG, et al.; for the Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metropolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaulation Study Investigators. N Engl J Med. 1999;341(10):709-717.
12. Pitt B, Remme W, Zannad F, et al.; for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348(22):2271]. N Engl J Med. 2003;348(14):1309-1321.
13. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551. (Pubitemid 39025171)
14. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547-1552. (Pubitemid 16114684)
15. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303-310.
16. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5(3):178-187.
17. Taylor AL, Ziesche S, Yancy C, et al.; for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure [published correction appears in N Engl J Med. 2005;352(12):1276]. N Engl J Med. 2004;351(20):2049-2057.
18. Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev. 2006;(1):CD003838.
19. Granger CB, McMurray JJ, Yusuf S, et al.; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776. (Pubitemid 37093917)
20. McMurray JJ, Ostergren J, Swedberg K, et al.; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting- enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771. (Pubitemid 37093916)
21. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336(8):525-533.
22. Adams KF Jr, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39(6):946-953. (Pubitemid 34234114)
23. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-878. (Pubitemid 37430346)
24. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403- 1411. (Pubitemid 35239712)
25. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329(1):1-7. (Pubitemid 23182871)